Literature DB >> 10530415

Clinical immunology of chronic cold agglutinin disease.

E Ulvestad1, S Berentsen, K Bø, F V Shammas.   

Abstract

We studied clinical and immunological characteristics of 15 patients with chronic cold agglutinin disease (CAD). Mean age at disease debut was 68 years for female and 67 years for male patients. The patients had no signs of other autoimmune diseases. All patients had V(H)4-34 encoded IgM kappa cold agglutinins (CA) in high titre. In five patients IgM increased significantly with advancing disease. Seven patients had reduced concentrations of lymphocytes, largely of CD4 and CD8 T cells. Percentages of NK cells (CD56) and B cells (CD19) were increased in seven and three patients, respectively. In six out of nine patients a clonal expansion of kappa positive B cells was found. Serum C3 was decreased in nine patients and C4 was decreased in 11 patients, six of whom had reduced CH50. Such data indicate that patients with CAD experience a continuous low-grade complement consumption. Five patients had experienced increased haemolysis during infections. After addition of active complement to patient sera in vitro, six sera showed increased haemolytic activity. Our results indicate that some patients with CAD have a relative deficit of complement in their serum and that an increase of complement production occurs during an acute phase reaction which enhances haemolysis. Our data also indicate that both CA titre and thermal amplitude are important characteristics when predicting complement activation and clinical course in CAD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10530415     DOI: 10.1111/j.1600-0609.1999.tb01887.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.

Authors:  A Vassou; V Alymara; A Chaidos; K L Bourantas
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 2.  Cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Therapy for chronic cold agglutinin disease: perspective for further improvements.

Authors:  Sigbjørn Berentsen
Journal:  Blood Transfus       Date:  2013-01-22       Impact factor: 3.443

4.  Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization.

Authors:  Megan Mullins; Xiaohui Jiang; Lauren C Bylsma; Jon P Fryzek; Heidi Reichert; Evan C Chen; Shivaani Kummar; Adam Rosenthal
Journal:  Blood Adv       Date:  2017-05-19

5.  Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.

Authors:  Hiroaki Tanaka; Shinichiro Hashimoto; Yasumasa Sugita; Shio Sakai; Yusuke Takeda; Daijiro Abe; Toshiyuki Takagi; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2012-08-11       Impact factor: 2.490

6.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24

7.  Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.

Authors:  Alexander Röth; Martin Bommer; Andreas Hüttmann; Dörte Herich-Terhürne; Nils Kuklik; Jan Rekowski; Veronika Lenz; Hubert Schrezenmeier; Ulrich Dührsen
Journal:  Blood Adv       Date:  2018-10-09

Review 8.  Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.

Authors:  Sigbjørn Berentsen; Tatjana Sundic
Journal:  Biomed Res Int       Date:  2015-01-29       Impact factor: 3.411

Review 9.  Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.

Authors:  Sigbjørn Berentsen; Klaus Beiske; Geir E Tjønnfjord
Journal:  Hematology       Date:  2007-10       Impact factor: 2.269

10.  Acute exacerbation of cold agglutinin disease during operation.

Authors:  Jinyoung Jeong; Hye Kyoung Lee; Eun-Su Choi; Wonsik Ahn
Journal:  Korean J Anesthesiol       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.